Objective: To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.

Material And Method: 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA.

Results: Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers.

Conclusion: The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567287PMC
http://dx.doi.org/10.1080/07357907.2021.1992420DOI Listing

Publication Analysis

Top Keywords

inactivated sars-cov-2
8
sars-cov-2 vaccine
8
immunogenicity safety
4
safety inactivated
4
vaccine
4
vaccine bbibp-corv
4
bbibp-corv patients
4
patients malignancy
4
malignancy objective
4
objective evaluate
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!